Author:
Calvo-Ortega Juan-Francisco,Moragues-Femenía Sandra,Laosa-Bello Coral,Torices-Caballero José,Hermida-López Marcelino,Casals-Farran Joan
Subject
Radiology Nuclear Medicine and imaging,Oncology
Reference33 articles.
1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): Patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial;Fransson;Lancet Oncol,2021
3. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer;Kishan;JAMA Netw Open,2019
4. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial;Brand;Lancet Oncol,2019
5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Prostate cancer, version 1.2020. Available at:https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459. Accessed March 16, 2020.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献